Carlos de Castro, MD
Hematology & Oncology · Durham, NCNPI 1912080169
Payments from drug & device makers
What this record shows
The money is spread across several categories — consulting fees (46.9%), speaking fees and travel and lodging — rather than concentrated in one kind of arrangement. 14 manufacturers reported payments, led by AstraZeneca at 47.5% of the total. Reporting peaked in 2023 at $40,070 and has fallen 68.0% since, to $12,815 in 2025. Among hematology & oncology clinicians in NC with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 105 payments — averaging $1182.82 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$59K
- Apellis Pharmaceuticals, Inc.$30K
- Novartis$8K
- Taiho Oncology, Inc.$6K
- Genentech, Inc.$6K
- E.r. Squibb & Sons, L.L.C.$6K
- plus $10K from 8 others
Across 47 payments — averaging $8464.69 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Novartis$177K
- Apellis Pharmaceuticals, Inc.$70K
- Bristol Myers Squibb$57K
- Daiichi Sankyo Inc.$50K
- AstraZeneca$32K
- Regeneron$10K
- plus $3K from 1 others
What the payments were for
- Consulting fees$58,20747%
- Speaking & faculty fees$56,11545%
- Travel & lodging$7,9766%
- Food & beverage$1,7391%
- Education$1600%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 45 | $58,985 |
| Apellis Pharmaceuticals, Inc. | 30 | $29,755 |
| Novartis | 9 | $8,036 |
| Taiho Oncology, Inc. | 3 | $5,938 |
| Genentech, Inc. | 3 | $5,846 |
| E.r. Squibb & Sons, L.L.C. | 1 | $5,536 |
| Agios Pharmaceuticals, Inc. | 2 | $3,840 |
| Gilead | 1 | $2,270 |
| Biocryst Pharmaceuticals, Inc. | 3 | $2,000 |
| Genentech USA, Inc. | 1 | $1,520 |
| Bristol Myers Squibb | 3 | $215 |
| Incyte Corporation | 2 | $149 |
| GSK | 1 | $95 |
| Pfizer | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$124,196 in reported general payments places this provider in the 90th percentile of 358 hematology & oncology providers in North Carolina.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EmpaveliPegcetacoplan | 13 | $615,196 |
| JakafiRuxolitinib Phosphate | 29 | $490,226 |
| VonjoPacritinib Citrate | 12 | $296,477 |
| IclusigPonatinib Hcl | 13 | $281,955 |
| InqoviDecitabine/Cedazuridine | 35 | $245,638 |
| TasignaNilotinib Hcl | 15 | $224,522 |
| VenclextaVenetoclax | 24 | $206,849 |
| BrukinsaZanubrutinib | 11 | $146,857 |
| Imatinib Mesylate | 41 | $6,225 |
| Cyclosporine ModifiedCyclosporine, Modified | 30 | $2,533 |
| Acyclovir | 14 | $152 |
| Ondansetron Hcl | 22 | $92 |
| Prednisone | 14 | $55 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Apellis Pharmaceuticals, Inc.Empaveli | $29,755 | $615,19613 claims |
| Incyte CorporationJakafi | $149 | $490,22629 claims |
| Taiho Oncology, Inc.Inqovi | $5,938 | $245,63835 claims |
| NovartisTasigna | $8,036 | $224,52215 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 358 hematology & oncology providers in North Carolina.
Other hematology & oncology in Durham
- Michael MorseDurham$2.6M
- Phillip FebboDurham$749K
- Matthew McKinneyDurham$277K
- Taewoong ChoiDurham$207K
- Ivy AltomareDurham$164K
- Jeffrey CrawfordDurham$125K
- Joseph MooreDurham$97K
- Ammon FagerDurham$56K
- Jameel MuzaffarDurham$31K
- Jeremy ForceDurham$30K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.